E
FDMT icon

Ergoteles’s 4D Molecular Therapeutics FDMT Stock Holding History

Ergoteles’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-35,922
Closed -$649K – 331
2023
Q2 		$649K Buy
+35,922
New +$661K 0.03% 584
2022
Q3 		– Sell
-20,600
Closed -$144K – 1676
2022
Q2 		$144K Buy
+20,600
New +$200K ﹤0.01% 1429

Other funds holding FDMT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Ergoteles's FDMT Position: Q3 2023 in Review

Ergoteles sold out of 4D Molecular Therapeutics (FDMT) in Q3 2023, closing a stake of 35,922 shares — an estimated $649K sold.

Ergoteles first reported a position in FDMT in Q2 2022 and held it in 2 quarters. The position peaked at $649K in Q2 2023. 110 funds tracked by Wall St. Rank hold FDMT as of Q3 2023.

  • Ergoteles reported no remaining 4D Molecular Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Ergoteles sold 35,922 4D Molecular Therapeutics shares in Q3 2023, an estimated $649K.
  • Ergoteles first reported a position in 4D Molecular Therapeutics in Q2 2022 and held it in 2 quarters.
  • Ergoteles's 4D Molecular Therapeutics position peaked at $649K in Q2 2023.
  • 110 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q3 2023.

Based on Ergoteles's 13F filing for Q3 2023, filed 14 Nov 2023.